Hemodialysis therapy in the United States: what is the dose and does it matter?
There is an ongoing discussion in the renal community about how to monitor the treatment of hemodialysis patients in the United States. Comparison of the US patient experience to that of other countries with populations of similar health status is one way to assess treatment. Another technique involves examining the level of dialysis therapy US patients receive. This paper reviews recent studies which found that the United States has higher mortality than both Japan and Europe and provides additional information as to why those comparisons might be underestimating the mortality differences. We also examine the data on the level of dialysis US patients receive, both as a prescription and as delivered care. We conclude that US patients receive less hemodialysis therapy than their European and Japanese counterparts, and that in general US patients are not receiving the level of dialysis they were prescribed. These factors are correlated with an increased mortality among US hemodialysis patients.
Held
P J
PJ
Department of Medicine, University of Michigan, Ann Arbor 48103.
Carroll
C E
CE
Liska
D W
DW
Turenne
M N
MN
Port
F K
FK
D005060:Europe / Q000453:epidemiology; D006801:Humans; D007564:Japan / Q000453:epidemiology; D007676:Kidney Failure, Chronic / Q000401:mortality / Q000628:therapy*; D016030:Kidney Transplantation / Q000401:mortality; D006435:Renal Dialysis / Q000401:mortality / Q000706:statistics & numerical data*; D015996:Survival Rate; D014481:United States / Q000453:epidemiology